Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals of the Week: Options Abound As Forest Keeps Its Eyes On A Prize-Winner

Executive Summary

Reflecting a long trend, three of this past week’s deals include option arrangements, including one with a new twist. Also, a rare disease partnership between Shire and Atlas Venture finally leads to a deal and Takeda continues building its vaccines business.

You may also be interested in...



To Jump Start China, Think Commercial: Amgen Ties Knot With Beta Pharma For Vectibix

Since fixing its eyes on China, Amgen has been scouting the country for deals. Now the first result is in, a JV with local industry darling Beta Pharma to commercialize Vectibix in China.

CTI Sees Ideal Pipeline Acquisition In JAK2 Inhibitor Abandoned By Onyx

Cell Therapeutics licenses Phase III pacritinib from Singapore’s S*BIO about a year after Onyx declined an option on the myelofibrosis candidate.

Shire And Atlas Venture To Work Together To Incubate Rare Disease Research Projects

Collaboration will create start-up biotechs to advance promising research in orphan indications, but the companies will not take a “cookie cutter” approach to structure or evolution.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel